PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biomarker Discovery

Background:

• Monoclonal antibodies targeting the PD-1/PD-L1 axis have transformed cancer therapy, improving patient survival.
• PD-L1 expression in tumor biopsies is the primary biomarker for predicting response to immunotherapy.
• However, many patients with PD-L1-positive tumors do not respond, necessitating better predictive biomarkers.

Purpose of the Study:

• To review the role of PD-L1 expression in predicting immunotherapy outcomes.
• To explore PD-L1 expression in both tumor cells and immune cells.
• To assess the influence of PD-L1 on immune cell subsets and antitumor activity.

Main Methods:

• Literature review of studies on PD-1/PD-L1 inhibitors in cancer treatment.
• Analysis of PD-L1 expression in tumor cells and tumor-infiltrating immune cells.
• Evaluation of the correlation between PD-L1 expression patterns and treatment response.

Main Results:

• PD-L1 expression on tumor cells alone is insufficient for accurate patient stratification.
• PD-L1 expression on immune cells offers additional predictive value for immunotherapy response.
• Combined analysis of PD-L1 in different cellular compartments may enhance prediction accuracy.

Conclusions:

• Beyond tumor cell PD-L1, immune cell PD-L1 expression is crucial for predicting immunotherapy efficacy.
• Further research into multifaceted PD-L1 expression patterns can optimize patient selection for cancer immunotherapy.
• Identifying novel biomarkers is essential to improve treatment outcomes and reduce healthcare costs associated with ineffective immunotherapies.